In a recent earnings call, Florian Funck, CFO of Sartorius Stedim Biotech, provided reassurance on the company’s order trends and explained their conservative guidance. He highlighted the improving book-to-bill ratio and absence of pull-forward demand trends. CEO also expressed confidence in the guidance, particularly in the Bioprocess Solutions segment. However, challenges in the Lab Products & Services segment and macroeconomic uncertainties are contributing factors to their conservative stance. What does this mean for Bioprocess EBITDA margins and the company’s future growth? According to recent reports, the company saw a nearly 9% year-over-year growth in Bioprocessing Solutions sales revenue in constant currency, with an underlying EBITDA of EUR527 million and a margin increase of 170 basis points to 29.8%. The company’s strong growth in consumables continues to be a significant driver of their overall business, with group revenue growing by 6% in constant currencies. This growth has led to a notable margin expansion driven by volume, product mix, and economies of scale. The underlying EBITDA increased by 12% year-over-year, bringing the margin close to 30%. Sartorius Stedim Biotech has also introduced several new products to enhance the efficiency and productivity of their customers’ drug development and manufacturing processes. For more detailed insights, refer to the full earnings call transcript available on finance.yahoo.com.
Tags: None
Read more from finance.yahoo.com